A tetrahydrocarbazole derivative showed dual NOX2 and NOX4 inhibition

What the study found: The study identified B1, a sulfonamide-substituted tetrahydrocarbazole derivative, as a dual inhibitor of NADPH oxidase 2 (NOX2) and NADPH oxidase 4 (NOX4). The authors describe it as showing isoform-selective dual inhibition and having drug-like properties.
Why the authors say this matters: The authors say upregulation of NOX2 and NOX4 contributes to traumatic brain injury (TBI)-induced oxidative stress and neurodegeneration, and they conclude that B1 is a promising scaffold for TBI neuroprotection. They also note that it was predicted to be blood-brain barrier (BBB)-permeable, which they present as relevant to this context.
What the researchers tested: The researchers designed, synthesized, and evaluated 19 sulfonamide-substituted tetrahydrocarbazole derivatives. They used molecular docking and 100-nanosecond molecular dynamics simulations with a NOX2 crystal structure and an AlphaFold-predicted NOX4 model, then synthesized the compounds by Borsche-Drechsel cyclization and tested them in HL-60 cells using ELISA kits to quantify NOX, NOX2, and NOX4 protein levels.
What worked and what didn't: B1 is the compound highlighted in the abstract, with reported values of 04.30 ± 0.26 ng/mL for NOX, 02.80 ± 0.04 ng/mL for NOX2, and 137.18 ± 3.67 pg/mL for NOX4. The abstract compares these values with GSK2795039 for NOX2 and GLX351322 for NOX4, but it does not provide a full comparative analysis of all 19 compounds.
What to keep in mind: The abstract does not describe detailed study limitations or safety testing. It also provides only a brief summary of the results, so the extent of B1's effectiveness beyond the reported in silico and in vitro findings is not shown here.

Key points

• B1, a sulfonamide-substituted tetrahydrocarbazole derivative, was identified as a dual NOX2 and NOX4 inhibitor.
• The authors link NOX2 and NOX4 upregulation to traumatic brain injury-related oxidative stress and neurodegeneration.
• The study tested 19 derivatives using molecular docking, molecular dynamics, synthesis, and HL-60 cell assays.
• B1 was described as having drug-like properties and predicted BBB permeability.
• The abstract does not give detailed limitations or broader validation beyond the reported in silico and in vitro work.